Trader consensus heavily favors no new COVID variant of concern before 2027 because current SARS-CoV-2 evolution remains confined to Omicron sublineages under monitoring, such as XFG, NB.1.8.1, and BA.3.2, without meeting WHO or ECDC criteria for elevated transmissibility, severity, or immune escape that would trigger a VOC designation. As of June 2026, ECDC lists zero active VOCs, with BA.3.2 detections rising modestly in parts of Europe but staying below 0.2% prevalence in U.S. surveillance and showing no meaningful increase in hospitalizations or deaths. Ongoing wastewater and genomic tracking indicate stable circulation patterns, consistent with predictable drift rather than abrupt shifts. This skin-in-the-game pricing reflects the low historical rate of VOC emergence in recent years and the absence of concerning signals through mid-2026.